Anti-SARS-CoV-2 IgG antibodies induced by the BNT162b2 mRNA vaccine is age-dependent and influenced by a previous natural SARS-CoV-2 infection

Main Article Content

Simone Pratò
Maria Emilia Paladino
Michele Augusto Riva
Annalisa Cavallero
Raffaele Latocca
Andrea Biondi
Paolo Bonfanti
Michael Belingheri


SARS, antibody, vaccine, BNT162b2, booster, third


Background and aim: our study aimed to investigate the association between anti-SARS-CoV-2 IgG level after two doses of BNT162b2 vaccine and the previously infected/infection-naïve status, age, and gender in a population of health care workers (HCWs).

Methods: all the population of immunocompetent HCWs were vaccinated with two doses of BNT162b2 based on a technical data sheet. SARS-CoV-2 IgG assay was performed 25 to 32 days after the second dose. Anti-SARS-CoV-2 IgG level was used as a categorical variable, since 2080 BAU/ml was the median IgG value. The multivariate logistic regression model included the previously infected/infection-naïve status, age groups, and gender.

Results: All HCWs tested were seropositive. The odds ratio (OR) for anti-SARS-CoV-2 IgG> 2080 BAU / ml between previously infected and infection-naïve HCWs was 2.05 [95% CI 1.1-3.8].  Older age groups had lower percentage of HCWs with anti-SARS-CoV-2 IgG> 2080 BAU / mL than younger groups. Finally, no association between gender and IgG level was found.

Conclusions:our study showed an excellent antibody response to vaccination with BNT162b2 after two doses. A significant difference was observed between anti-SARS-CoV-2 IgG level with age and previous SARS-CoV-2 infection status.


Download data is not yet available.
Abstract 420 | PDF Downloads 189


1. Angyal A, Longet S, Moore S, et al. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. Lancet Microbe. 2021 Nov 9 [Epub ahead of print].
2. Prendecki M, Clarke C, Brown J, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. The Lancet. 2021 Mar;397(10280):1178–81.
3. Zimmermann P, Curtis N. Factors That Influence the Immune Response to Vaccination. Clinical Microbiology Reviews. 2019 Mar 13;32(2).
4. Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nature Medicine. 2020 Jul 12;26(7):1033–6.
5. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020 Oct 22;586(7830):516–27.
6. Keech C, Albert G, Cho I, et al. Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. New England Journal of Medicine. 2020 Dec 10;383(24):2320–32.
7. Poh CM, Carissimo G, Wang B, et al. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. Nature Communications. 2020 Dec 1;11(1):2806-13.
8. Walsh EE, Frenck RW, Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine. 2020 Dec 17;383(25):2439–50.
9. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine. 2020 Dec 31;383(27):2603–15.
10. Belingheri M, Paladino ME, Piacenti S, Riva MA. Effects of COVID-19 lockdown on epidemic diseases of childhood. J Med Virol. 2020 Jul 11 [Epub ahead of print].
11. Belingheri M, Paladino ME, Latocca R, De Vito G, Riva MA. Association between seasonal flu vaccination and COVID-19 among healthcare workers. Occupational Medicine. 2020 Dec 30;70(9):665–71.
12. Angel Y, Spitzer A, Henig O, et al. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. JAMA [Internet]. 2021 May 6; Available from:
13. DiaSorin. LIAISON® SARS-CoV-2 TrimericS IgG assay. 2021.
14. Ebinger JE, Fert-Bober J, Printsev I, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nature Medicine. 2021 Apr 1;1–4.
15. Müller L, Andrée M, Moskorz W, et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. Clin Infect Dis. 2021;ciab381 [Epub ahead of print].
16. Gustafson CE, Kim C, Weyand CM, Goronzy JJ. Influence of immune aging on vaccine responses. Journal of Allergy and Clinical Immunology. 2020 May;145(5):1309–21.
17. Pera A, Campos C, López N, et al. Immunosenescence: Implications for response to infection and vaccination in older people. Maturitas. 2015 Sep;82(1):50–5.
18. Frasca D, Blomberg BB. Aging induces B cell defects and decreased antibody responses to influenza infection and vaccination. Immunity & Ageing. 2020 Dec 19;17(1):37-47.

Most read articles by the same author(s)